BriaCell Therapeutics (NASDAQ:BCTX) Shares to Reverse Split on Wednesday, January 29th

BriaCell Therapeutics Corp. (NASDAQ:BCTX) shares are set to reverse split on the morning of Wednesday, January 29th. The 1-15 reverse split was announced on Friday, January 3rd. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, January 28th.

BriaCell Therapeutics Stock Performance

Shares of BCTX opened at $0.40 on Monday. BriaCell Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $4.61. The company has a market capitalization of $17.56 million, a P/E ratio of -0.34 and a beta of 1.55. The business’s 50-day moving average is $0.70 and its two-hundred day moving average is $0.76.

BriaCell Therapeutics (NASDAQ:BCTX) last posted its earnings results on Monday, December 16th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). Analysts forecast that BriaCell Therapeutics will post -1.01 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of BriaCell Therapeutics in a research note on Thursday, December 12th.

Institutional Trading of BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned about 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.